MacroGenics has announced the sale of its clinical and commercial drug substance production portfolio for $122.5 million upfront, a strategic move aimed at refocusing its resources on core therapeutic areas. This divestiture underscores a growing trend among biopharmaceutical companies to streamline operations and concentrate on innovation while outsourcing manufacturing capabilities to specialized partners. The decision reflects the increasing pressures within the industry to enhance operational efficiency and reduce costs, particularly in a landscape where regulatory compliance and quality assurance are paramount.
In a separate development, West Pharmaceutical Services disclosed a cybersecurity attack that has raised concerns about the integrity of its operations and the potential impact on its supply chain. As the pharmaceutical sector becomes more digitized, the risk of cyber threats has escalated, prompting companies to bolster their cybersecurity measures. This incident serves as a stark reminder for industry players to prioritize data protection and resilience against cyber threats to safeguard their operations and maintain trust with stakeholders.
Use the database as your supply chain compass →
